← back to search

Kang Li

Kunming University of Science and Technology · CN
🔎 Find collaborators in Molecular Biology · Oncology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Molecular Biology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Ferroptosis and cancer prognosis, Metabolomics and Mass Spectrometry Studies, and Cancer-related molecular mechanisms research.
h-index
44
citations
6,744
works
304
NIH funding
primary concept
email

Recent publications

Autophagy in <scp>PE</scp> : Dispute, Role and Potential Target
Cell Proliferation 2025cited by 4position: middledoi
Predicting response and survival of lung adenocarcinoma under anti-programmed death-1 therapy using biological deep learning
Briefings in Bioinformatics 2025cited by 3position: middledoi
Predicting response and survival of lung adenocarcinoma under anti-programmed death-1 therapy using biological deep learning.
2025cited by 2position: contributordoi
A cell-interacting and multi-correcting method for automatic circulating tumor cells detection
Artificial Intelligence in Medicine 2025cited by 0position: contributordoi
Single cell analysis unveils B cell-dominated immune subtypes in HNSCC for enhanced prognostic and therapeutic stratification
International Journal of Oral Science 2024cited by 25position: firstdoi
Shaping immune landscape of colorectal cancer by cholesterol metabolites
EMBO Molecular Medicine 2024cited by 21position: middledoi
BiMPADR: A Deep Learning Framework for Predicting Adverse Drug Reactions in New Drugs
Molecules 2024cited by 8position: lastdoi
Improving compound-protein interaction prediction by focusing on intra-modality and inter-modality dynamics with a multimodal tensor fusion strategy
Computational and Structural Biotechnology Journal 2024cited by 3position: middledoi
Nomogram Predicts Prognostic Factors for Head and Neck Cutaneous Melanoma: A Population-Based Analysis
World Neurosurgery 2024cited by 3position: lastdoi
A Novel Competing Endogenous RNA Network Reveals Potential Mechanisms and Biomarkers of Chemoresistance in Lung Adenocarcinoma
Journal of Cancer 2024cited by 2position: lastdoi
Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.
2024cited by 2position: contributordoi
Advances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
Pharmaceuticals 2023cited by 79position: middledoi
E2EFP-MIL: End-to-end and high-generalizability weakly supervised deep convolutional network for lung cancer classification from whole slide image
Medical Image Analysis 2023cited by 37position: middledoi
E2EFP-MIL: End-to-end and high-generalizability weakly supervised deep convolutional network for lung cancer classification from whole slide image
Medical Image Analysis 2023cited by 37position: contributordoi
Biologically Interpretable Deep Learning To Predict Response to Immunotherapy In Advanced Melanoma Using Mutations and Copy Number Variations
Journal of Immunotherapy 2023cited by 5position: lastdoi
Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts
Journal of Molecular Medicine 2023cited by 3position: middledoi
A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma
Pharmaceuticals 2023cited by 2position: middledoi
Improving ovarian cancer treatment decision using a novel risk predictive tool
Aging 2022cited by 13position: middledoi
<scp>LncRNA</scp> ‐412.25 activates the <scp>LIF</scp> / <scp>STAT3</scp> signaling pathway in ovarian granulosa cells of Hu sheep by sponging <scp>miR</scp> ‐346
The FASEB Journal 2022cited by 12position: middledoi
Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer
Genes 2022cited by 11position: middledoi
A Novel Risk Score to Predict In-Hospital Mortality in Patients With Acute Myocardial Infarction: Results From a Prospective Observational Cohort
Frontiers in Cardiovascular Medicine 2022cited by 4position: lastdoi
A novel subtype to predict prognosis and treatment response with DNA driver methylation–transcription in ovarian cancer
Epigenomics 2022cited by 2position: middledoi
A novel subtype to predict prognosis and treatment response with DNA driver methylation-transcription in ovarian cancer.
2022cited by 2position: contributordoi
Biologically interpretable deep learning to predict response to immunotherapy in advanced melanoma using mutations and copy number variations
Research Square 2022cited by 1position: lastdoi
LncRNA-UCA1 regulates lung adenocarcinoma progression through competitive binding to miR-383
Figshare 2022cited by 1position: middledoi
Methylation biomarkers with discriminating ability are potential therapeutic targets in lung adenocarcinoma.
2022cited by 1position: contributordoi
A novel attention-guided convolutional network for the detection of abnormal cervical cells in cervical cancer screening
Medical Image Analysis 2021cited by 102position: middledoi
Deficiency of Mettl3 in Bladder Cancer Stem Cells Inhibits Bladder Cancer Progression and Angiogenesis
Frontiers in Cell and Developmental Biology 2021cited by 45position: middledoi
The Discovery of New Drug-Target Interactions for Breast Cancer Treatment
Molecules 2021cited by 22position: lastdoi
WaveICA 2.0: a novel batch effect removal method for untargeted metabolomics data without using batch information
Metabolomics 2021cited by 21position: middledoi

Grants

EAGER: Development of Model-Based Active Chair for Proactive Injury Prevention
NSF1555408$300,0002015–2018PIRePORTER
CSR: Small: Detecting Flaws in Virtual Devices by Conformance Checking
NSF1319115$440,7252013–2017PIRePORTER
SBIR Phase I: Early Detection of Software and Hardware Flaws by Conformance Checking and Virtual Prototyping
NSF1315391$127,9722013–2013PIRePORTER
CT-T: Collaborative Research: Adaptive Attacks and Defenses in Denial of Information
NSF0716357$246,8532007–2011PIRePORTER

Frequent collaborators

Yan Hou · Merck & Co., Inc., Rahway, NJ, USA (United States)30 papers (2012–2022)Kui Deng · Nanchang University19 papers (2017–2021)Zhiwei Rong · Harbin Medical University18 papers (2017–2022)Kai Yang · Union Hospital18 papers (2014–2020)Weiwei Zhao · University of Iowa16 papers (2017–2023) · 15 papers (2019–2025)Hongyu Xie · The University of Western Australia13 papers (2015–2022)Liuchao Zhang · Beijing Institute of Technology13 papers (2020–2025)Zhenzi Li · Harbin Medical University12 papers (2012–2020)Liuying Wang · Harbin Medical University12 papers (2020–2025)Chaofu Ke · Harbin Medical University12 papers (2012–2018)Chunyan Yang · North Sichuan Medical University11 papers (2017–2020)Lei Cao · Tianjin First Center Hospital10 papers (2020–2024)Ge Lou · Harbin Medical University9 papers (2012–2017)Lijun Fan · Second Affiliated Hospital of Zhejiang University8 papers (2012–2024)Fengyu Sun · Harbin Medical University7 papers (2013–2020)Fan Zhang · Nanjing Agricultural University7 papers (2014–2018)Haiyu Zhang · Harbin Medical University7 papers (2012–2020)Lei Cao · Nanchang University7 papers (2022–2025)Zheng‐Jiang Zhu · Shanghai University7 papers (2018–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Molecular Biology · Oncology →